Q Does maintenance aripiprazole prevent relapse in people with chronic schizophrenia with residual symptomatology?


**MAIN RESULTS**
Aripiprazole significantly decreased relapse rate compared with placebo (Kaplan-Meier survival rates at week 26: 62.6% with aripiprazole vs 39.4% with placebo; p<0.001; RR for relapse 0.50, 95% CI 0.35 to 0.71). Aripiprazole significantly improved schizophrenic symptoms compared with placebo at 26 weeks (PANSS total score, CGI-S and CGI-I scales; see table). Both groups had a similar incidence of adverse effects (79.7% with aripiprazole v 77.1% with placebo).

**CONCLUSIONS**
Aripiprazole is effective for preventing relapse in people with chronic schizophrenia and residual symptomatology over a six month period.
Aripiprazole is effective for relapse prevention in people with chronic stable schizophrenia

_Evid Based Mental Health_ 2004 7: 41
doi: 10.1136/ebmh.7.2.41

Updated information and services can be found at:
http://ebmh.bmj.com/content/7/2/41

These include:

**References**
This article cites 2 articles, 0 of which you can access for free at:
http://ebmh.bmj.com/content/7/2/41#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Schizophrenia spectrum (430)
- Drugs: psychiatry (344)
- Substance dependence (407)
- Clinical trials (epidemiology) (989)
- Delirium (20)
- Epidemiology (1570)
- Neurology (1070)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/